The US Federal Trade Commission announced Wednesday that pharmaceutical giant Novartis offered to divest its nicotine patch Habitrol to secure clearance for a joint venture.
Reports say Novartis offered the concessions to reduce competition concerns over its proposed partnership with UK-based GlaxoSmithKline. The agreement would see Novartis acquiring Glaxo’s oncology drugs portfolio, while Glaxo would take on Novartis’s non-flu vaccines operations.
But according to reports, the two conglomerates are among just three companies that sell nicotine patches to US retailers. Reports did not indicate whether the FTC will accept the concessions offered, however.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Uruguayan Antitrust Scrutiny Puts Major Meatpacking Deal Between Marfrig and Minerva on Hold
May 19, 2024 by
CPI
Alaska Airlines Seeks Dismissal of Consumer Lawsuit Over $1.9 Billion Hawaiian Airlines Buy
May 19, 2024 by
CPI
Idaho Attorney General Orders Split of Kootenai Health and Syringa Hospital
May 19, 2024 by
CPI
Court Rejects T-Mobile’s Appeal Bid in Antitrust Case Over Sprint Merger
May 19, 2024 by
CPI
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI